Published Date: 10 Mar 2023
Today's top stories include: Nine-year cap to complete MBBS, elective-based credits offered in NMC letter Students enrolled in...
Read Full NewsA randomized trial questions whether patients with standard-risk multiple myeloma need indefinite lenalidomide maintenance.
A phase 2 trial evaluates the benefit of adding blinatumomab to consolidation therapy in adults with high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.
1.
In Patients with Myeloma Who Postpone HSCT, Quadruplet Displays "Excellent Activity.".
2.
Black women have a higher risk of dying from all types of breast cancer, meta-analysis reveals
3.
Second opinions don't significantly delay breast cancer treatment
4.
Year in Review: Multiple Myeloma
5.
Adding Daratumumab to VRd Boosts MRD Negativity in Transplant-Ineligible Myeloma
1.
The importance of understanding normal serum osmolality
2.
Unlocking the Secret to Accurate ANC Calculation with This Informative Blog Post
3.
What is Red Cell Distribution Width and Why Should You Care?
4.
Metabolic Vulnerabilities in Solid Tumor Progression
5.
Exploring the Normal Range of Monocytes: A Comprehensive Guide
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
3.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation